Results 131 to 140 of about 6,305 (264)

Proton boron capture therapy: microdosimetry and treatment planning study with boron. [PDF]

Front Oncol
Yoo SH, Sedliarou I, MacDiarmid JA, Brahmbhatt H, Han S, Kim KB, Tran LT, Rosenfeld AB, Kim EH, Lin YH, Tan WS, Cheah YY, Wong RX, Looi WS, Ho S, Han KB, Yeo P, Djeng SK.   +17 more
europepmc   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

[Patient complaints in primary care in a Spanish region (2018-2024): A quantitative analysis]. [PDF]

Aten Primaria
Pérez-Jiménez A, Font Jiménez I, Hernández Fernández F.   +2 more
europepmc   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

Impact of acromegaly subtypes on survival: results from a large multicenter cohort. [PDF]

J Endocr Soc
Cuevas-Ramos D, Labadzhyan A, Gomez D, Fox R, Martínez-Sánchez FD, Rocha-Haro A, Gómez-Pérez FJ, Melmed S.   +7 more
europepmc   +1 more source

Control óptimo de problemas elípticos lineal-cuadráticos

, 2017
Grado en ...
openaire   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

Editorial: 3^rd international workshop on microdosimetry for particle therapy: Bridging physics and biology. [PDF]

Precis Radiat Oncol
Barna S, Conte V, Cordoni F, Missiaggia M, Guan F, Rozenfeld A, Santa Cruz G, Sato T, Schettino G, La Tessa C.   +9 more
europepmc   +1 more source

Control no lineal con compensación "feedforward" empleando redes neuronales

, 1994
Fil: Calvo, Rafael A.. Universidad Nacional de Rosario - CONICET. Instituto de Física de Rosario (IFIR).
Basualdo, Marta Susana, Calvo, Rafael A., Ceccatto, Hermenegildo Alejandro   +2 more
openaire   +2 more sources

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source